<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05071872</url>
  </required_header>
  <id_info>
    <org_study_id>PMCF-Arteriovenous Graft</org_study_id>
    <nct_id>NCT05071872</nct_id>
  </id_info>
  <brief_title>PMCF of Rotarex®S &amp; Aspirex®S Catheters in Treating Thrombotic Occlusion of Arteriovenous Graft</brief_title>
  <official_title>Retrospective Post-Market Clinical Follow Up of Rotarex®S &amp; Aspirex®S Catheters in Treating Thrombotic Occlusion of Arteriovenous Graft for Dialysis Access (Artificial Bypass)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Straub Medical AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Straub Medical AG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Retrospective Post-Market Clinical Follow Up of Rotarex®S &amp; Aspirex®S Catheters in treating&#xD;
      thrombotic occlusion of Arteriovenous Graft for dialysis access (Artificial Bypass)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To evaluate the safety, technical performance, and clinical efficacy of the Rotarex®S &amp;&#xD;
      Aspirex®S Catheters as a stand-alone and adjunctive therapy for the treatment of acute&#xD;
      thrombotic occlusion of arteriovenous graft for dialysis access (Artificial Bypass) in&#xD;
      accordance with Rotarex®S &amp; Aspirex®S Catheters intended use.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 6, 2021</start_date>
  <completion_date type="Actual">June 8, 2022</completion_date>
  <primary_completion_date type="Actual">June 8, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Technical success</measure>
    <time_frame>Day 1</time_frame>
    <description>defined as removal of thrombotic occlusion in AV-G with Rotarex®S or Aspirex®S Catheter</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Procedural success</measure>
    <time_frame>Day 1</time_frame>
    <description>defined as restoration of blood flow in AV-G following Rotarex®S or Aspirex®S Catheter ± adjunctive treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Successful use of AV-Graft as dialysis access</measure>
    <time_frame>Up to 14 days</time_frame>
    <description>Successful use of AV-Graft as dialysis access post-procedure on at least two occasions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Primary and Secondary Patency</measure>
    <time_frame>10 days, 1, 3 and 6 months</time_frame>
    <description>defined as ability to perform dialysis at 10 days, 1 month, 3 months and 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(SAEs) Serious Adverse events Rate</measure>
    <time_frame>6 months</time_frame>
    <description>SAEs as defined per ISO 14155</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedure-related Adverse events Rate</measure>
    <time_frame>6 months</time_frame>
    <description>Procedure-related AEs as defined per ISO 14155</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(ADEs) Adverse device effects Rate</measure>
    <time_frame>6 months</time_frame>
    <description>Adverse device effects (ADEs) as defined per ISO 14155</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(SADEs) Serious Adverse Device Effects Rate</measure>
    <time_frame>6 months</time_frame>
    <description>(SADEs) Serious Adverse Device Effects as defined per ISO 14155</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">127</enrollment>
  <condition>Arteriovenous Graft Thrombosis</condition>
  <arm_group>
    <arm_group_label>Rotarex®S</arm_group_label>
    <description>Treatment performed with Rotarex®S</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aspirex®S</arm_group_label>
    <description>Treatment performed with Aspirex®S</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Atherectomy/Thrombectomy</intervention_name>
    <description>Percutaneous transluminal removal of thrombotic occlusion in arteriovenous graft</description>
    <arm_group_label>Aspirex®S</arm_group_label>
    <arm_group_label>Rotarex®S</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Acute thrombotic occlusion of arteriovenous graft for dialysis access (Artificial Bypass)&#xD;
        treated with either Rotarex®S Catheter nor Aspirex®S Catheter&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Female or male subject with a minimum age of 18 years&#xD;
&#xD;
          2. Treatment performed between 2013 and 2020&#xD;
&#xD;
          3. Occlusion in arteriovenous graft&#xD;
&#xD;
          4. For the Rotarex®S group: use of Rotarex®S Catheter&#xD;
&#xD;
          5. For the Aspirex®S group: use of Aspirex®S Catheter&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        1. Subjects not appropriate for this study according to the opinion of the principal&#xD;
        investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Samuel Heller, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Angiocentrum Příbram</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Angiocentrum Příbram</name>
      <address>
        <city>Příbram</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czechia</country>
  </location_countries>
  <verification_date>December 2021</verification_date>
  <study_first_submitted>September 27, 2021</study_first_submitted>
  <study_first_submitted_qc>September 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 8, 2021</study_first_posted>
  <last_update_submitted>February 8, 2023</last_update_submitted>
  <last_update_submitted_qc>February 8, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">February 9, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

